Do the EMA accelerated assessment procedure and the FDA priority review ensure a therapeutic added value? 2006–2015: a cohort study - Université des Antilles Access content directly
Journal Articles European Journal of Clinical Pharmacology Year : 2016

Do the EMA accelerated assessment procedure and the FDA priority review ensure a therapeutic added value? 2006–2015: a cohort study

No file

Dates and versions

hal-02473455 , version 1 (10-02-2020)

Identifiers

Cite

Denis Boucaud-Maitre, Jean-Jacques Altman. Do the EMA accelerated assessment procedure and the FDA priority review ensure a therapeutic added value? 2006–2015: a cohort study. European Journal of Clinical Pharmacology, 2016, 72 (10), pp.1275-1281. ⟨10.1007/s00228-016-2104-3⟩. ⟨hal-02473455⟩

Collections

UNIV-AG
30 View
0 Download

Altmetric

Share

Gmail Facebook X LinkedIn More